Dr. Gyongyi Szabo

Gyongyi Szabo, MD, PhD is the Mitchell T. Rabkin, M.D. Chair, a professor of Medicine and Faculty Dean at Harvard Medical School and Chief Academic Officer at the Beth Israel Deaconess Medical Center and Beth Israel Lahey Health.

A physician-scientist and an internationally known expert in liver diseases. Dr. Szabo investigates the complex role of chronic inflammation in the progression of liver diseases.  Her laboratory studies the cellular and molecular mechanisms of inflammation and innate immunity in liver injury to identify therapeutic targets focused on non-alcoholic liver disease, NASH and alcoholic liver disease. Her translational research with the use of IL-1 receptor antagonist in a preclinical model of alcoholic hepatitis provided basis for a subsequent first-time clinical trial in alcoholic hepatitis with IL-1 inhibition. She is the lead investigator on the AlcHeptNet NIH-supported multicenter clinical trial in alcoholic hepatitis. Dr. Szabo has experience in Investigator-Initiated clinical trials in NASH and she participated as PI in over 30 industry-supported clinical trials in hepatitis C infection, NASH and other liver diseases. Dr. Szabo is a member of the Hungarian Academy of Sciences, and fellow of the AASLD, AGA and the American College of Physicians (ACP). Dr. Szabo has served on scientific advisory boards of biotech and pharmaceutical companies to help design and evaluate clinical trials. Dr. Szabo served on the Governing Board and as president of the American Association for the Study of Liver Diseases (AASLD) in 2015.